Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Kidney disease

XOR risk variants drive diabetic kidney disease

Diabetic kidney disease is influenced by a combination of genetic and environmental factors. A study identifies risk variants in the XOR promoter that elevate its own activity in response to hyperglycaemia, which has a causative role in the onset and progression of diabetic kidney disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Risk variants of XOR promoter increase XOR expression, leading to excess ROS and mitochondrial damage that cause DKD.

References

  1. Reidy, K., Kang, H. M., Hostetter, T. & Susztak, K. J. Clin. Invest. 124, 2333–2340 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Clin. J. Am. Soc. Nephrol. 12, 2032–2045 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Susztak, K., Raff, A. C., Schiffer, M. & Böttinger, E. P. Diabetes 55, 225–233 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Jha, J. C., Banal, C., Chow, B. S., Cooper, M. E. & Jandeleit-Dahm, K. Antioxid. Redox Signal. 25, 657–684 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Polito, L., Bortolotti, M., Battelli, M. G. & Bolognesi, A. Pharmacol. Res. 184, 106407 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. Wang, Q. et al. Nat. Metab. https://doi.org/10.1038/s42255-023-00776-0 (2023).

  7. Qi, Z. et al. Diabetes 54, 2628–2637 (2005).

    Article  CAS  PubMed  Google Scholar 

  8. Kottaisamy, C. P. D., Raj, D. S., Prasanth Kumar, V. & Sankaran, U. Lab. Anim. Res. 37, 23 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Day, R. O., Kamel, B., Kannangara, D. R., Williams, K. M. & Graham, G. G. Clin. Sci. 130, 2167–2180 (2016).

    Article  CAS  Google Scholar 

  10. Ohtsubo, T. et al. Hypertension 54, 868–876 (2009).

    Article  CAS  PubMed  Google Scholar 

  11. Huber, R., Pietsch, D., Panterodt, T. & Brand, K. Cell. Signal. 24, 1287–1296 (2012).

    Article  CAS  PubMed  Google Scholar 

  12. Zhang, J. et al. FASEB J. 28, 1511–1525 (2014).

    Article  CAS  PubMed  Google Scholar 

  13. Herbelin, A., Ureña, P., Nguyen, A. T., Zingraff, J. & Descamps-Latscha, B. Kidney Int. 39, 954–960 (1991).

    Article  CAS  PubMed  Google Scholar 

  14. Theilade, S. et al. J. Intern. Med. 277, 362–371 (2015).

    Article  CAS  PubMed  Google Scholar 

  15. Wei, C. et al. Nat. Med. 17, 952–960 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jochen Reiser.

Ethics declarations

Competing interests

J.R. is co-founder and co-chair of Walden Biosciences, a company targeting kidney diseases.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, K., Reiser, J. XOR risk variants drive diabetic kidney disease. Nat Metab 5, 536–537 (2023). https://doi.org/10.1038/s42255-023-00768-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-023-00768-0

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing